Free Trial
NASDAQ:CMPX

Compass Therapeutics Q3 2024 Earnings Report

Compass Therapeutics logo
$2.14 -0.01 (-0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.14 +0.00 (+0.23%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Compass Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Compass Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Compass Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Compass Therapeutics Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Compass Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email.

About Compass Therapeutics

Compass Therapeutics (NASDAQ:CMPX), a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

View Compass Therapeutics Profile

More Earnings Resources from MarketBeat